1. Bioequivalence Assessment of Metformin Tablet Formulations of Bangladesh.
- Author
-
Islam, M. A., Islam, A., Khan, M. R. I., Sharmin, R., Wahed, M. I. I., and Anisuzzaman, A. S. M.
- Subjects
METFORMIN ,HYPOGLYCEMIC agents ,STREPTOZOTOCIN ,DIABETES ,DRUG tablets - Abstract
Six marketed oral antidiabetic metformin tablets in Bangladesh have been studied for their drug content, release profile and glucose lowering capacities. This sort of study is a good indicator for in vivo evaluation of the quality of an oral antidiabetic preparation. Marketed preparations of metformin-HCl from different manufacturers were randomly chosen for this study. The drug content was within the United State Pharmacopoeia (USP) specified limit (95-105%) in all cases. The blood glucose levels were investigated in streptozotocin-induced diabetic rats (SIDRs) after 5 hours of single dose (110 mg/kg body weight) treatment of the products; significantly (p<0.05) reduced blood glucose level by 58.1, 53.2, 50.8, 77.0, 72.9 and 49.1%, respectively; which were consistent with antihyperglycemic effects of standard metformin-HCl (71.3%). All the products were found to be qualified in lowering blood glucose level. It may be inferred that the metformin-HCl tablets of Bangladeshi manufacturers complies with the standard specifications for drug contents, dissolution and antihyperglycemic properties. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF